Focused On-demand Library for Small ribosomal subunit protein uS15m

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

P82914

UPID:

RT15_HUMAN

Alternative names:

28S ribosomal protein S15, mitochondrial

Alternative UPACC:

P82914; B2RD82; Q9H2K1

Background:

The Small ribosomal subunit protein uS15m, also known as 28S ribosomal protein S15, mitochondrial, plays a crucial role in the mitochondrial ribosome. It is involved in the synthesis of proteins within the mitochondria, a process essential for cellular energy production and metabolic functions. The protein's unique structure and function within the mitochondrial ribosome make it a subject of interest for understanding mitochondrial biology and its impact on cellular health.

Therapeutic significance:

Understanding the role of Small ribosomal subunit protein uS15m could open doors to potential therapeutic strategies. Its critical function in protein synthesis within mitochondria highlights its importance in cellular metabolism and energy production, suggesting that targeting this protein could offer new avenues for treating diseases related to mitochondrial dysfunction.